Region’s First Early Detection Alzheimer’s Centre Lunches in Abu Dhabi

Abu Dhabi is set to open the Middle East and North Africa’s first centre dedicated to the early biochemical detection of Alzheimer’s disease, offering advanced blood tests that can identify risk as early as age 40. Developed by the National Reference Laboratory (NRL), part of the M42 Group, in partnership with Neurocode International, the centre is scheduled to launch within two months.

Replacing invasive diagnostic procedures, the new facility will use blood-based biomarkers to detect early signs of Alzheimer’s years before symptoms appear—providing a critical window for early intervention. With no known cure and over 55 million people affected globally, early detection is expected to support preventive action, including lifestyle adjustments and targeted drug therapies that may slow disease progression.

The centre will also support diagnostics for other neurological disorders, including Parkinson’s disease and myasthenia gravis, and is positioned to become one of the region’s most advanced brain health laboratories. It will serve both local and international patients, with discussions underway regarding insurance coverage and final location.